VJHemOnc is committed to improving our service to you

CAR-T Meeting 2020 | An exciting era for immunotherapy for R/R ALL

VJHemOnc is committed to improving our service to you

Arnon Nagler

Arnon Nagler, MD, Sheba Medical Center, Tel-Aviv, Israel, discusses the exciting field of immunotherapy in relapsed refractory (R/R) acute lymphoblastic leukemia (ALL). Two monoclonal antibodies; blinatumomab, and inotuzumab are now available for ALL as well as CAR T-cell therapy for patients up to the age of 25 years. This interview took place at the 2nd European CAR T-Cell Meeting in Sitges, Spain.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter